ITGR trades 18.7% below Wall Street's consensus target of $108.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ITGR achieves its forward estimates and maintains a stable P/E multiple of 15.0x. This scenario reflects the blended consensus of 15 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 22, 2026, Integer Holdings Corporation (ITGR) has a Wall Street consensus price target of $108.00, based on estimates from 15 covering analysts. With the stock currently trading at $90.96, this represents a potential upside of +18.7%. The company has a market capitalization of $3.13B.
Analyst price targets range from a low of $101.00 to a high of $115.00, representing a 13% spread in expectations. The median target of $108.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 12 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ITGR trades at a trailing P/E of 31.5x and forward P/E of 15.0x. The forward PEG ratio of 3.40 reflects a premium valuation. Analysts expect EPS to grow +47.7% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $147.13, with bear and bull scenarios of $92.69 and $193.85 respectively. Model confidence stands at 46/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
NVCRNovoCure Limited | $1.6B | $14.28 | $33.00 | +131.1% | Buy | — | 15 |
LIVNLivaNova PLC | $4.3B | $78.50 | $79.86 | +1.7% | Buy | 18.5x | 14 |
ANIKAnika Therapeutics, Inc. | $193M | $14.42 | — | — | Buy | — | 6 |
LAKELakeland Industries, Inc. | $99M | $10.08 | $15.67 | +55.5% | Buy | — | 9 |
ATRCAtriCure, Inc. | $1.5B | $28.80 | $51.33 | +78.2% | Buy | 768.0x | 19 |
ABTAbbott Laboratories | $153.7B | $88.38 | $127.46 | +44.2% | Buy | 16.1x | 41 |
MDTMedtronic plc | $101.9B | $79.34 | $95.80 | +20.7% | Buy | 13.3x | 51 |
BSXBoston Scientific Corporation | $67.3B | $45.29 | $82.90 | +83.0% | Buy | 13.5x | 44 |
SYKStryker Corporation | $117.9B | $307.80 | $387.46 | +25.9% | Buy | 20.5x | 51 |
ZBHZimmer Biomet Holdings, Inc. | $17.2B | $87.97 | $96.33 | +9.5% | Hold | 10.4x | 42 |
Quick answers to the most common questions about buying ITGR stock.
Integer Holdings Corporation (ITGR) has a consensus 12-month price target of $108, implying 18.7% upside from $90.96. The 15 analysts covering ITGR see moderate appreciation potential.
ITGR has a consensus rating of "Buy" based on 15 Wall Street analysts. The rating breakdown is predominantly bullish, with 12 Buy/Strong Buy ratings. The consensus 12-month price target of $108 implies 18.7% upside from current levels.
With a forward P/E of 14.9544x, ITGR trades at a relatively low valuation. The consensus target of $108 implies 18.7% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $115 for ITGR, while the most conservative target is $101. The consensus of $108 represents the median expectation. Our quantitative valuation model projects a bull case target of $194 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
ITGR is well covered by analysts, with 15 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 12 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ITGR stock forecast based on 15 Wall Street analysts shows a consensus price target of $108, with estimates ranging from $101 (bear case) to $115 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $147, with bear/bull scenarios of $93/$194.
Our quantitative valuation model calculates ITGR's fair value at $147 (base case), with a bear case of $93 and bull case of $194. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 46/100.
ITGR trades at a forward P/E ratio of 15.0x based on next-twelve-months earnings estimates compared to a trailing P/E of 31.5x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are optimistic on ITGR, with a "Buy" consensus rating and $108 price target (18.7% upside). 12 of 15 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ITGR analyst price targets range from $101 to $115, a 13% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $108 consensus represents the middle ground. Our model's $93-$194 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.